There is a quiet revolution happening in medicine — and Asia is right at the centre of it. Cell and gene therapy, once the exclusive domain of academic research papers and early-phase clinical trials, is rapidly becoming a commercial reality across the Asia-Pacific region. Governments are rewriting regulatory frameworks, manufacturers are racing to establish regional manufacturing hubs, and patients with previously untreatable conditions are, for the first time, accessing therapies that were science fiction a generation ago. But navigating the regulatory landscape across Asia for cell and gene therapy is not for the faint-hearted. It is a patchwork of evolving frameworks, divergent approval pathways, and wildly different timelines — and understanding it is increasingly a strategic necessity for any organisation operating in this space.
🧬 Why Asia Matters for Cell & Gene Therapy Right Now
The numbers make the case clearly. The global cell and gene therapy market was valued at approximately USD 19.8 billion in 2024 and is projected to reach USD 89.3 billion by 2032, growing at a compound annual growth rate of roughly 20.6%. Asia-Pacific is expected to be the fastest-growing regional segment across that entire forecast period — driven by a combination of large patient populations, significant government investment in biotechnology infrastructure, and a growing appetite among regulators to position their markets as destinations for advanced therapy innovation.
China alone accounted for over 40% of all global cell and gene therapy clinical trials registered in 2024 — a figure that reflects both the scale of the country’s biomedical research infrastructure and the relative speed with which its regulatory system has adapted to accommodate advanced therapy development. Japan, South Korea, and Australia have each developed distinct regulatory frameworks that offer meaningful advantages for specific development strategies. And emerging markets including Taiwan, Singapore, and India are actively building the regulatory infrastructure needed to attract advanced therapy investment.
🇨🇳 China: Scale, Speed, and a Maturing Framework
China’s regulatory journey with cell and gene therapy has been, to put it diplomatically, eventful. The 2018 He Jiankui gene-edited baby scandal sent shockwaves through the global scientific community and prompted a significant tightening of China’s regulatory oversight of gene editing and germline modification. But the regulatory response that followed has been substantive and largely constructive — and China’s cell and gene therapy regulatory framework today is considerably more sophisticated than its pre-2018 predecessor.
The National Medical Products Administration (NMPA) has developed a dedicated regulatory pathway for cell and gene therapy products under its Innovative Drug Fast Track designation, which can reduce standard review timelines from the conventional 200 working days to as few as 60 working days for products addressing serious or life-threatening conditions with significant unmet need. The NMPA’s 2023 guidelines on somatic cell therapy and gene therapy products established clearer requirements for manufacturing quality, clinical evidence standards, and post-approval safety monitoring — providing a more predictable development pathway than had previously existed.
The data on approvals reflects this maturation. By the end of 2025, China had approved 11 cell and gene therapy products for commercial use — including CAR-T therapies, gene-modified cell therapies, and oncolytic virus products — with a further 23 products in late-stage regulatory review. The NMPA has also established a conditional approval pathway that allows products demonstrating substantial early clinical evidence to reach patients while confirmatory data is generated post-approval — a mechanism that has significantly accelerated patient access for several haematological malignancy indications.
The challenge in China remains manufacturing quality consistency. A 2025 audit review by the NMPA found that 34% of cell and gene therapy manufacturing facilities inspected had received observations related to process validation, contamination control, or batch release documentation — a figure that underscores the gap between the pace of clinical and regulatory development and the maturation of the manufacturing ecosystem.
🇯🇵 Japan: The SAKIGAKE Advantage
Japan occupies a genuinely distinctive position in the global cell and gene therapy regulatory landscape — and it is one that the country has cultivated deliberately. The SAKIGAKE designation, introduced by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2015 and significantly expanded in subsequent years, provides an accelerated approval pathway for innovative therapies that offers some of the fastest regulatory timelines available anywhere in the world.
Under SAKIGAKE, qualifying cell and gene therapy products can receive priority consultation, rolling review of clinical data, and a target total review time of six months from submission to approval decision — compared to a standard review timeline of approximately 12 months under the conventional PMDA pathway. For products that also qualify under Japan’s conditional and time-limited approval system — which allows approval based on limited clinical evidence with mandatory post-marketing confirmatory studies — the pathway to commercial availability can be remarkably compressed.
Japan approved its first CAR-T therapy in 2019 and has since built one of the most active advanced therapy approval records in the Asia-Pacific region. By mid-2026, 17 cell and gene therapy products held commercial approval in Japan — a figure that places the country second only to China in terms of approved advanced therapy products within the region.
The PMDA has also invested significantly in its scientific advisory infrastructure for advanced therapies, establishing a dedicated Cell and Gene Therapy Review Division in 2022 that has substantially reduced the variability in regulatory guidance that had previously been a source of frustration for developers navigating the Japanese pathway.
🇰🇷 South Korea: Building Regional Ambition
South Korea’s Ministry of Food and Drug Safety (MFDS) has been quietly building one of the most progressive advanced therapy regulatory frameworks in Asia — and the investment is beginning to show results. South Korea approved its first domestically developed CAR-T therapy in 2024 — a milestone that reflected both the maturation of the country’s cell therapy manufacturing sector and the MFDS’s growing confidence in its capacity to evaluate complex advanced therapy submissions.
The MFDS operates a conditional approval pathway for advanced therapy medicinal products that is broadly analogous to Japan’s conditional and time-limited approval system, allowing products with promising early clinical data to reach patients while post-marketing confirmatory evidence is generated. Review timelines under the standard MFDS pathway run approximately 180 days for advanced therapy products, with priority review reducing this to approximately 120 days for products addressing serious unmet needs.
South Korea’s strategic ambition in cell and gene therapy extends beyond domestic market access. The government’s Bio-Health Industry Innovation Strategy, updated in 2025, included a specific commitment to positioning South Korea as a regional cell and gene therapy contract development and manufacturing organisation hub — with targeted investment of approximately USD 2.1 billion in advanced therapy manufacturing infrastructure over the 2025–2030 period.
🌏 Singapore and Australia: The Regulatory Sophistication Play
Singapore and Australia occupy a different strategic position in the Asia-Pacific cell and gene therapy landscape — one defined less by market scale and more by regulatory sophistication, intellectual property protection, and manufacturing quality standards that align closely with European and international benchmarks.
Singapore’s Health Sciences Authority (HSA) operates a well-regarded advanced therapy regulatory framework that has attracted significant regional headquarters investment from global cell and gene therapy developers. The HSA’s collaborative registration pathway — which allows products approved by reference regulatory authorities including the European Medicines Agency to be reviewed on an expedited basis — has reduced average approval timelines for qualifying products to approximately 120 days, compared to a standard review period of around 270 days.
Australia’s Therapeutic Goods Administration (TGA) has similarly developed a streamlined pathway for advanced therapy products, with its Priority Review designation offering a 50% reduction in standard evaluation fees and a target review timeline of 150 working days — alongside a well-established clinical trial notification system that has made Australia a preferred destination for early-phase cell and gene therapy clinical development in the region.
📊 A Comparative Snapshot
Here is how the major Asia-Pacific regulatory frameworks compare across the dimensions most relevant to cell and gene therapy developers:
| Market | Regulatory Body | Accelerated Pathway | Target Review Timeline | Approved CGT Products (mid-2026) |
|---|---|---|---|---|
| China | NMPA | Innovative Drug Fast Track | 60 working days | 11 |
| Japan | PMDA | SAKIGAKE + Conditional Approval | 6 months | 17 |
| South Korea | MFDS | Conditional Approval | 120–180 days | 6 |
| Singapore | HSA | Collaborative Registration | ~120 days | 4 |
| Australia | TGA | Priority Review | 150 working days | 9 |
The table reflects publicly available regulatory data as of mid-2026. Approval counts include products with active commercial marketing authorisations.
💡 What This Means for Developers
The Asia-Pacific cell and gene therapy regulatory landscape rewards strategic planning far more than it rewards reactive navigation. The key takeaways from the current landscape are clear.
Japan remains the fastest credible pathway to commercial approval for products with early but compelling clinical evidence — particularly for rare disease and oncology indications where the SAKIGAKE and conditional approval mechanisms can be combined to maximum effect.
China offers unmatched scale but demands genuine investment in manufacturing quality infrastructure and a realistic assessment of the post-approval commitments that accompany conditional approvals.
Singapore and Australia offer the most predictable and internationally aligned regulatory environments — making them natural choices for regional clinical development strategies and for organisations seeking regulatory approvals that will support broader international submissions.
The region as a whole is moving in a consistent direction: faster pathways, more adaptive approval mechanisms, and a growing recognition that the conventional evidence standards developed for small-molecule pharmaceuticals do not translate cleanly to the biology and manufacturing realities of advanced therapies.
For developers willing to engage early, plan strategically, and invest in the regulatory relationships that accelerate review, Asia-Pacific represents not just a market opportunity — but a genuine competitive advantage in the global race to bring cell and gene therapies to patients.
